ClearLight Closes Lab Services and Offers Expert Consulting Services Learn More

ClearLight Biotechnologies Announces Issuance of U.S. Patent No. 10,545,075

Posted on Jan 28, 2020

Patent expands IP portfolio licensed from Stanford

SUNNYVALE, CA., Jan. 28, 2020 – ClearLight Biotechnologies is pleased to announce that the United States Patent and Trademark Office has issued U.S. Patent No. 10,545,075 – “METHODS AND COMPOSITIONS FOR PREPARING BIOLOGICAL SPECIMENS FOR MICROSCOPIC ANALYSIS” – more popularly known as the CLARITY method.

The ‘075 patent describes methods and compositions to prepare a biological specimen for 3D microscopic analysis without sectioning into thin 2D slices, maintaining the spatial morphology and microenvironment of the specimen. Coupled with immunohistochemistry (IHC) and in situ hybridization (ISH), the CLARITY methods can find many applications in medicine and preclinical research, such as in immuno-oncology, personalized medicine, monitoring disease or graft transplantation, anatomic pathology, and in preclinical drug development. Researchers involved in preclinical drug development can leverage these methods for specific research studies, narrowing studies, combination studies and toxicology and safety studies to advance drug candidates for clinical trial. Also included in the patent are reagents, devices, kits and systems relating to the CLARITY technology. The ‘075 patent contains 33 claims and expires in May 2033.

This newly allowed patent, owned by Stanford University in Palo Alto, California, is exclusively licensed to ClearLight Biotechnologies for clinical use. “We are extremely pleased with the issuance of this patent, which demonstrates the development of the patent portfolio we licensed from Stanford. We have continued to improve and develop these methods and techniques. ClearLight’s service model makes these techniques available to researchers in the U.S. and worldwide.” said Al Hansen, President of ClearLight. “Dr. Deisseroth’s CLARITY method is the foundation of our tissue processing workflow, 3D Immunohistochemistry, and imaging and analysis software. Imaging biomarkers in 3D reveals novel insights, unobtainable with other technology. Our entire team is excited about its future.”

About ClearLight Biotechnologies, Inc.

Founded by Karl Deisseroth M.D., Ph.D., ClearLight Biotechnologies provides pharmaceutical, biotechnology, and academic researchers with CLARITY Tissue Clearing, 3D immunostaining, and Tru3D image analysis services. ClearLight technology is based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technology, paired with proprietary 3D image analysis software in development, empowers researchers to “See More Biology” within the tissue microenvironment. ClearLight Biotechnologies is developing technologies to improve diagnostic, prognostic, and predictive treatment of disease so we can all live healthier lives.

Learn more about ClearLight by visiting the company online at:



Contact: Al Hansen, President




Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: